Program
GS3-007a dry suspension
Its studies are mostly in Dwarfism, Pituitary, led by Changchun GeneScience Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | 21 open or running | phase 2since Nov 13, 2025 | Nov 13, 2025 | Nov 2030phase 2 · NCT07264595 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 13, 2025First studies: 2 phase 2 studiesFirst studyNCT07259564, NCT07264595
Ahead
- Nov 2030Primary completion: phase 2 study in Pediatric Growth Hormone DeficiencyNCT07264595
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07264595Pediatric Growth Hormone Deficiency · China | 2 | Recruiting | Nov 2030 | 88 |
| NCT07259564Dwarfism, Pituitary · China | 2 | Terminated | Apr 15, 2026 | 120 |
How it is read
Names in the registry
- “GS3-007a dry suspension”, 2 entries
Conditions, from the studies’ own filings
- Dwarfism, Pituitary, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.